ClinicalTrials.gg
CompletedNCT01101035CARESUpdated Jun 14, 2018Results posted

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

A Phase 3 interventional study of Febuxostat and Allopurinol in Cardiovascular Disease, sponsored by Takeda. Completed at 203 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-06-14.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,198
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).

Read the detailed description

The drug tested in this study was called Febuxostat (TMX-67). Febuxostat compared with allopurinol was evaluated for the cardiovascular (CV) safety in people with gout and significant CV comorbidities.

The study enrolled 6198 patients. Participants with a diagnosis of gout were enrolled in a 1:1 ratio to receive either:

  • Febuxostat
  • Allopurinol

Participants received febuxostat 40 mg or 80 mg for the study depending on their serum uric acid levels were either \<6.0 mg/dL or ≥6.0 mg/dL during specified visits. Allopurinol 200 mg to 400 mg (for moderate renal impairment),or 300 mg to 600 mg (for normal and mild renal impairment), increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL was received.

This multi-center trial was conducted in Canada, Mexico and United States. The overall time to participate in this study was approximately 7 years (84 months). Participants made multiple visits to the clinic and were also contacted through the telephone.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Cardiovascular Outcomes
  • Heart Attack
  • Stroke
  • Drug Therapy
  • Physiology
  • Hyperuricemia
  • Uric Acid
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's enrollment of 6,198 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant or the participant's legally acceptable representative signs and dates a written, form/Health Insurance Portability and Accountability Act (HIPAA) Authorization prior to the initiation of any study procedures.
  2. The participant is male ≥50 years of age or female ≥55 years of age and at least 2-years .
  3. The participant has a history of major CV or cerebrovascular disease including at least one of the following:

    • Myocardial infarction (MI).
    • Hospitalized unstable angina.
    • Cardiac or cerebrovascular revascularization procedure.
    • Stroke.
    • Hospitalized (TIA).
    • Peripheral vascular disease (ankle brachial index ≤0.6, revascularization and/or well-documented history of claudication).
    • History of diabetes mellitus with evidence of micro- or macrovascular disease (retinopathy, neuropathy, nephropathy, small vessel vascular diseases).
  4. The participant has a history or presence of gout defined as having one or more of the American Rheumatism Association criteria for the diagnosis of gout:

    • A tophus proven to contain urate crystals by chemical or polarized light microscopic means, and/or
    • Characteristic urate crystals in the joint fluid, and/or
    • History of at least 6 of the following clinical, laboratory, and X-ray phenomena:

      • More than 1 attack of acute arthritis.
      • Maximum inflammation developed within 1 day.
      • Monoarticular arthritis.
      • Redness observed over joints.
      • First metatarsophalangeal joint painful or swollen.
      • Unilateral first metatarsophalangeal joint attack.
      • Unilateral tarsal joint attack.
      • Tophus (proven or suspected).
      • Hyperuricemia.
      • Asymmetric swelling within a joint on x-ray.
      • Subcortical cysts without erosions on x-ray.
      • Joint fluid culture negative for organisms during attack.
  5. The participants must have either:

    • a serum urate or serum uric acid (sUA) level ≥7.0 mg/dL (≥416 μmol/L) at the Day -7 Visit OR
    • a sUA level ≥6.0 mg/dL (≥354 μmol/L) at the Day -7 Visit AND inadequately controlled gout (≥1 flare in the 12 months prior to screening and/or the presence of tophi).
  6. The participant is capable of understanding and complying with protocol requirements

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will not qualify for entry into this study:

  1. The participant has secondary hyperuricemia (eg, due to myeloproliferative disorder, or organ transplant).
  2. The participant has a history of xanthinuria.
  3. The participant has received urate-lowering therapy (i.e., febuxostat, allopurinol, probenecid, etc.) or excluded medication during the screening period (beginning with Day -7).
  4. The participant has a known to febuxostat or allopurinol or any components of their formulation.
  5. The participant has active peptic ulcer disease.
  6. The participant has a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior to the first dose of study medication.
  7. The participant had MI or stroke within 60 days prior to the Screening Visit.
  8. The participant has (ALT) and/or aspartate aminotransferase (AST) values greater than 2 times the (×ULN) during the Screening period.
  9. The participant has a significant medical condition and/or conditions that would interfere with the treatment, safety, or compliance with the protocol.
  10. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit or the participant consumes >14 alcoholic beverages per week.
  11. The participant has received any medicinal product within the 30 days prior to the Screening Visit and throughout the study.
  12. The participant's estimated (CLcr) is \<30 mL/min, where CLcr is calculated using the Cockcroft and Gault formula based on ideal body weight (IBW),
  13. The participant is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  14. The participant is required to take excluded medications
  15. The participant has a known history of infection with , , or .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,198 participants (actual)

Study arms

  • Experimental
    Febuxostat

    Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.

    Drug: Febuxostat

  • Active comparator
    Allopurinol

    Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance \[eCLcr\] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but \<60 mL/min).

    Drug: Allopurinol

Interventions

  • Febuxostat tablets

    Also known as: Uloric, TMX-67

  • Allopurinol tablets

    Also known as: Zyloprim, Allohexal, Allosig, Milurit, Alloril, Progout, Zyloric, Puricos, Zyrik 300, Aluron

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)

    Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.

    Time frame: Up to last dose of study drug (approximately 83 months)

  2. Percentage of Participants With Primary MACE Composite (Final Analysis)

    Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.

    Time frame: Up to last dose of study drug (approximately 83 months)

Secondary outcomes

  1. Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event

    APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.

    Time frame: Up to last dose of study drug (approximately 83 months)

  2. Percentage of Participants With Cardiovascular (CV) Death

    Events were adjudicated by an independent cardiovascular endpoints committee as CV death.

    Time frame: Up to last dose of study drug (approximately 83 months)

  3. Percentage of Participants With Non-fatal Myocardial Infarction (MI)

    Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.

    Time frame: Up to last dose of study drug (approximately 83 months)

  4. Percentage of Participants With Non-fatal Stroke

    Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.

    Time frame: Up to last dose of study drug (approximately 83 months)

  5. Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization

    Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.

    Time frame: Up to last dose of study drug (approximately 83 months)

07

Results

Posted Jun 14, 2018

Participant flow

Participants took part in the study at 320 investigative sites in Canada, Mexico and United States from 23 April 2010 to 18 July 2017.

Participant flow — Overall Study
MilestoneFebuxostatAllopurinol
Started31013097
Completed17041706
Not completed13971391
Withdrew: Adverse event191172
Withdrew: Major protocol deviation5246
Withdrew: Lost to follow-up226223
Withdrew: Voluntary withdrawal595587
Withdrew: Reason not specified333363

Outcome measures

PrimaryPercentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)

Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)8.08.0
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 0.99Time from randomization to the first occurrence of any MACE was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function as a stratification factor.
SecondaryPercentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event

APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event9.68.8
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 1.09 · 95% CI 0.92 to 1.28Time from randomization to the first occurrence of any APTC event was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function status as a stratification factor.
SecondaryPercentage of Participants With Cardiovascular (CV) Death

Events were adjudicated by an independent cardiovascular endpoints committee as CV death.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Cardiovascular (CV) Death
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Cardiovascular (CV) Death4.33.2
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 1.34 · 95% CI 1.03 to 1.73Time from randomization to the first occurrence of cardiovascular death was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.
SecondaryPercentage of Participants With Non-fatal Myocardial Infarction (MI)

Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-fatal Myocardial Infarction (MI)
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Non-fatal Myocardial Infarction (MI)3.63.8
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 0.93 · 95% CI 0.72 to 1.21Time from randomization to the first occurrence of non-fatal MI was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.
SecondaryPercentage of Participants With Non-fatal Stroke

Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-fatal Stroke
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Non-fatal Stroke2.32.3
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 1.01 · 95% CI 0.73 to 1.41Time from randomization to the first occurrence of non-fatal stroke was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.
SecondaryPercentage of Participants With Unstable Angina With Urgent Coronary Revascularization

Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization1.61.8
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 0.86 · 95% CI 0.59 to 1.26Time from randomization to the first occurrence of unstable angina with urgent coronary revascularization was fitted using Cox Proportional Hazard model with factors including treatment and baseline renal function.
PrimaryPercentage of Participants With Primary MACE Composite (Final Analysis)

Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.

Time frame:
Up to last dose of study drug (approximately 83 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Primary MACE Composite (Final Analysis)
percentage of participantsFebuxostatAllopurinol
Percentage of Participants With Primary MACE Composite (Final Analysis)10.810.4
Statistical analysis
  • Febuxostat vs Allopurinol · Cox proportional hazard: 1.03 · 97% CI 0.87 to 1.23Time from randomization to the first occurrence of any MACE was fitted using Cox Proportional Hazard model with treatment as a covariate and Baseline renal function as a stratification factor.

Adverse events

Collected over First dose of study drug to 30 days after last dose of study drug (Approximately 84 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat243/3,098 (7.8%)1,046/3,098 (33.8%)1,450/3,098 (46.8%)
Allopurinol199/3,092 (6.4%)995/3,092 (32.2%)1,467/3,092 (47.4%)
Most frequent serious events
Showing 10 of 844
Most frequent serious events
EventFebuxostatAllopurinol
Acute kidney injuryRenal and urinary disorders139/3098132/3092
Cardiac failure congestiveCardiac disorders124/3098109/3092
PneumoniaInfections and infestations67/309888/3092
Angina pectorisCardiac disorders74/309859/3092
Acute myocardial infarctionCardiac disorders63/309868/3092
Atrial fibrillationCardiac disorders65/309864/3092
Coronary artery diseaseCardiac disorders51/309858/3092
Myocardial infarctionCardiac disorders41/309851/3092
Cerebrovascular accidentNervous system disorders45/309844/3092
Acute respiratory failureRespiratory, thoracic and mediastinal disorders34/309843/3092
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFebuxostatAllopurinol
ArthralgiaMusculoskeletal and connective tissue disorders258/3098311/3092
DiarrhoeaGastrointestinal disorders299/3098284/3092
Upper respiratory tract infectionInfections and infestations242/3098267/3092
HypertensionVascular disorders209/3098261/3092
Pain in extremityMusculoskeletal and connective tissue disorders222/3098218/3092
Back painMusculoskeletal and connective tissue disorders216/3098187/3092
BronchitisInfections and infestations214/3098212/3092
Oedema peripheralGeneral disorders168/3098183/3092
Urinary tract infectionInfections and infestations146/3098180/3092
Blood creatine phosphokinase increasedInvestigations148/3098161/3092

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.

Age, Continuous
Age, Continuous(years)FebuxostatAllopurinolTotal
Mean64.6 ± 8.5865.0 ± 8.4964.8 ± 8.53
Age, Customized
Age, Customized(Participants)FebuxostatAllopurinolTotal
<65 years158415063090
65 to <75 years109411352229
≥75 years420451871
Sex: Female, Male
Sex: Female, Male(Participants)FebuxostatAllopurinolTotal
Female494500994
Male260425925196
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FebuxostatAllopurinolTotal
American Indian or Alaska Native262234496
Asian9296188
Black or African American5525931145
Native Hawaiian or Other Pacific Islander131427
White216021404300
Other191534
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FebuxostatAllopurinolTotal
Hispanic or Latino5395211060
Not Hispanic or Latino255925715130
Region of Enrollment
Region of Enrollment(Participants)FebuxostatAllopurinolTotal
Canada6872140
Mexico379355734
United States265126655316
Height
Height(cm)FebuxostatAllopurinolTotal
Mean172.9 ± 9.54173.0 ± 9.77173.0 ± 9.65
Weight
Weight(kg)FebuxostatAllopurinolTotal
Mean100.5 ± 22.47100.3 ± 22.89100.4 ± 22.68

10 further baseline measures are reported on the registry.

08

Study locations

203 sites
  • Decatur, Georgia, United States
  • Dunwoody, Georgia, United States
  • Marietta, Georgia, United States
  • Norcross, Georgia, United States
  • Roswell, Georgia, United States
  • Suwanee, Georgia, United States
  • Waycross, Georgia, United States
  • Honolulu, Hawaii, United States
  • Boise, Idaho, United States
  • Coeur d'Alene, Idaho, United States
  • Nampa, Idaho, United States
  • Addison, Illinois, United States
  • Arlington Heights, Illinois, United States
  • Evanston, Illinois, United States
  • Evergreen Park, Illinois, United States
  • Flossmoor, Illinois, United States
  • Melrose Park, Illinois, United States
  • Morton, Illinois, United States
  • Naperville, Illinois, United States
  • Quincy, Illinois, United States
  • Rockford, Illinois, United States
  • Bloomington, Indiana, United States
  • Brownsburg, Indiana, United States
  • Lafayette, Indiana, United States
  • Valparaiso, Indiana, United States
  • Iowa City, Iowa, United States
  • Lenexa, Kansas, United States
  • Overland Park, Kansas, United States
  • Topeka, Kansas, United States
  • Wichita, Kansas, United States
  • Elizabethtown, Kentucky, United States
  • Lexington, Kentucky, United States
  • Owensboro, Kentucky, United States
  • Paducah, Kentucky, United States
  • Mer Rouge, Louisiana, United States
  • Monroe, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Biddeford, Maine, United States
  • Rockport, Maine, United States
  • Baltimore, Maryland, United States
  • Cumberland, Maryland, United States
  • Hagerstown, Maryland, United States
  • Lutherville, Maryland, United States
  • Wheaton, Maryland, United States
  • Brockton, Massachusetts, United States
  • Fall River, Massachusetts, United States
  • Hyannis, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Bingham Farms, Michigan, United States
  • Chelsea, Michigan, United States
  • Detroit, Michigan, United States
  • Flint, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Lansing, Michigan, United States
  • Chaska, Minnesota, United States
  • Duluth, Minnesota, United States
  • Edina, Minnesota, United States
  • Saint Paul, Minnesota, United States
  • Jackson, Mississippi, United States
  • Olive Branch, Mississippi, United States
  • Port Gibson, Mississippi, United States
  • Clarkson Valley, Missouri, United States
  • Hazelwood, Missouri, United States
  • Kansas City, Missouri, United States
  • Saint Charles, Missouri, United States
  • Saint Louis, Missouri, United States
  • Washington, Missouri, United States
  • Billings, Montana, United States
  • Butte, Montana, United States
  • Bellevue, Nebraska, United States
  • Grand Island, Nebraska, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Reno, Nevada, United States
  • Brick, New Jersey, United States
  • Edison, New Jersey, United States
  • Oradell, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Las Vegas, New Mexico, United States
  • Endwell, New York, United States
  • Freeport, New York, United States
  • Glens Falls, New York, United States
  • Mineola, New York, United States
  • New Windsor, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • West Seneca, New York, United States
  • Westfield, New York, United States
  • Asheboro, North Carolina, United States
  • Cary, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Columbia, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Huntersville, North Carolina, United States
  • Lenoir, North Carolina, United States
  • Monroe, North Carolina, United States
  • Raleigh, North Carolina, United States

Showing the first 100 of 203 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012 Jul;164(1):14-20. doi: 10.1016/j.ahj.2012.04.011. Epub 2012 Jun 13. PubMed 22795277 ↗
  • White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. PubMed 29527974 ↗
  • Saag KG, Becker MA, White WB, Whelton A, Borer JS, Gorelick PB, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 Sep;74(9):1593-1601. doi: 10.1002/art.42160. Epub 2022 Aug 5. PubMed 35536764 ↗
  • Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17. PubMed 21849262 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in May 2017, 84 months.

Results were first posted in Jun 2018, 1 year after primary completion.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 84 months is above that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2010
First posted
Apr 9, 2010
StartActual
Apr 23, 2010
Primary completionActual
May 15, 2017
CompletionActual
Jul 18, 2017
Results first posted
Jun 14, 2018
Last update
Jun 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01101035
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 9, 2010
Start date
Apr 23, 2010
Primary completion
May 15, 2017
Completion
Jul 18, 2017
Results posted
Jun 14, 2018
Last update
Jun 14, 2018

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion